Lilly stretches Olumiant timeline, updates cancer strategy
By Jaime De Leon | Jul 26, 2017 | 2:08 AM GMT
Eli Lilly and Co. (NYSE:LLY) reported 2Q17 earnings and said it would delay its plans to resubmit an NDA for Olumiant baricitinib beyond 2017. The company also said it would narrow its oncology focus to prioritize a
Read the full 376 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury